A US Food and Drug Administration advisory panel suggested several ways the agency could improve the safety of higher dosage strength opioid products, from better storage and disposal, to specialized training and an FDA direct-to-consumer advertising campaign.
Members of FDA's Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee met...